GlassScriptPhysician profile
Satvinder Dhillon
NPI 1437296548
$9,296.44
in general payments reported to CMS, 2019-2025
54 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,297 · 2020: $1,619 · 2021: $1,398 · 2022: $1,083 · 2023: $1,320 · 2024: $1,158 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $991.90 | 2019-2025 | Jardiance, Tradjenta, Trijardy Xr |
| Novo Nordisk INC | $928.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $818.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amneal Pharmaceuticals LLC | $712.52 | 2020-2025 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $439.03 | 2019-2022 | |
| Astellas Pharma US INC | $407.92 | 2019-2021 | |
| Amgen INC. | $350.67 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $327.64 | 2021-2025 | |
| Amarin Pharma, INC. | $327.18 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $321.37 | 2019-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $304.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $267.57 | 2019-2021 | |
| Pfizer INC. | $252.62 | 2020-2025 | |
| Abbvie INC. | $245.91 | 2019-2025 | Synthroid |
| Mannkind Corporation | $232.31 | 2020-2025 | Afrezza |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $204.06 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $150.84 | 2021-2025 | Minimed 780g |
| Sanofi Pasteur INC. | $149.42 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $131.91 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $121.96 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Pharmaceuticals, INC | $120.59 | 2019-2022 | |
| Insulet Corporation | $112.82 | 2023-2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $111.54 | 2019-2022 | |
| Abbott Laboratories | $108.77 | 2020-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $97.83 | 2021-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $87.85 | 2023 | Arexvy, Shingrix |
| Corcept Therapeutics | $81.12 | 2021-2025 | Korlym |
| Tolmar, INC. | $77.82 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $71.32 | 2022-2024 | Strensiq |
| Eisai INC. | $63.13 | 2019 | |
| Becton, Dickinson and Company | $59.61 | 2020-2022 | |
| Vivus LLC | $59.17 | 2020-2022 | |
| Lifescan, INC. | $44.98 | 2020-2022 | |
| Medtronic Minimed, INC. | $44.28 | 2019 | |
| Halozyme INC | $42.51 | 2023 | |
| Valeritas, INC. | $38.30 | 2019 | |
| Ascensia Diabetes Care US INC. | $35.75 | 2025 | |
| Recordati_rare_diseases_inc. | $32.38 | 2025 | Isturisa |
| Clarus Therapeutics INC. | $28.24 | 2021 | |
| Daiichi Sankyo INC. | $28.16 | 2022-2024 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $27.36 | 2020 | |
| Allergan, INC. | $26.42 | 2019 | |
| Shire North American Group INC | $26.10 | 2019 | |
| Global Blood Therapeutics, INC. | $25.38 | 2022 | |
| Zealand Pharma US, INC. | $20.64 | 2021 | |
| Madrigal Pharmaceuticals | $18.55 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $17.74 | 2022 | |
| Ibsa Pharma INC. | $17.16 | 2025 | Flector, Licart, Tirosint |
| Esperion Therapeutics, INC. | $15.51 | 2025 | Nexletol |
| Radius Health, INC. | $14.91 | 2020 | |
| Opko Pharmaceuticals, LLC | $14.88 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.59 | 2021 | |
| Intuity Medical INC | $13.02 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satvinder Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.